98%
921
2 minutes
20
Noxa is a weak apoptosis activator consisting of a BH3 domain and a mitochondrial-targeting domain (MTD). BH3 binds Mcl-1 and Bcl2A1 and inactivates their anti-apoptotic activities, while MTD delivers BH3 to mitochondria. Previously we revealed that MTD may also function as an inducer of necrosis via conjugation with octa-arginine, which induces cytosolic Ca influx from mitochondria. However, the mechanism(s) underlying this process has not been elucidated yet. Here, we show that calcium influx induced by an MTD peptide fused with octa-arginine residue (R8:MTD) originates not only from mitochondria but also from the extracellular space. However, calcium spikes were not sufficient for necrosis. R8:MTD induced mitochondrial permeability transition pore opening, fragmentation, and swelling. These mitochondrial events induced by MTD appeared to be necessary for necrosis induction, since DIDS, a VDAC inhibitor, inhibited the mitochondrial swelling and cell death induced by MTD. We show that R8:MTD disrupted endoplasmic reticulum (ER) structures but not peroxisomes or Golgi, indicating that R8:MTD causes necrosis by inducing ER events as well.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bbrc.2019.08.011 | DOI Listing |
Anticancer Res
September 2025
Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan, R.O.C.;
Background/aim: Stereotactic ablative radiotherapy (SABR) can deliver tumoricidal doses to hepatocellular carcinoma (HCC). To date, there is a paucity of research reporting the impact of maximal tumor diameter (MTD) on patients with HCC treated with SABR.
Patients And Methods: The medical records of patients with HCC with Barcelona Clinic Liver Cancer (BCLC) stage A to C diseases treated with linear accelerator-based SABR between 2015 and 2021 were reviewed.
J Immunother Cancer
August 2025
Institut Gustave-Roussy, Villejuif, France.
Background: Inducible costimulator (ICOS) receptor belongs to the CD28/CTLA immunoglobulin super family, whose expression is restricted to T cells and is weakly expressed on resting TH17, follicular helper T cells, and regulatory T cells, but is highly induced on CD4+ and CD8+ T cells on activation by T-cell receptors. ICOS stimulation downstream effects include activation of conventional CD4+cells and cytotoxic CD8+cells, resulting in a durable antitumor response in preclinical models.
Methods: As part of a larger first-in-human study (GSK Study 204691), this study focused on 2 cohorts of 25 and 67 participants enrolled in a dose escalation and pharmacokinetic/pharmacodynamic (PK/PD) analysis of the ICOS agonist feladilimab (GSK3359609) as monotherapy.
Breast Cancer Res Treat
October 2025
Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medicine, Chicago, IL, USA.
Purpose: Preclinical models of glucocorticoid receptor (GR)-positive breast cancer (BC) and ovarian cancer (OC) suggest GR activity inhibits chemotherapy-induced apoptosis, and GR antagonism using mifepristone (Mif) enhances cytotoxicity. We performed a phase I trial combining mifepristone, carboplatin (C), gemcitabine (G).
Methods: A standard "3 + 3" dose escalation scheme was used.
J Complement Integr Med
August 2025
Graduate Studies, Chulabhorn International College of Medicine, Thammasat University, Pathumthani, Thailand.
Objectives: Psoriasis is a systematic skin disease. Treatment choice is limited due to unsatisfactory clinical efficacy. The study evaluated the safety of Deprungsith formulation following long-term administration (chronic toxicity test) and its potential modulatory effect on hepatic cytochrome P450 (CYP) enzymes in rats.
View Article and Find Full Text PDFBlood Neoplasia
August 2025
Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany.
A novel T-cell bispecific antibody (TCB), RO7283420, engaging CD3 and the HLA-A2-Wilms tumor protein 1 complex, was evaluated in this phase 1 study to characterize safety and tolerability, determine the maximum tolerated dose (MTD), and recommend a phase 2 dose for patients with relapsed/refractory acute myeloid leukemia in 2 groups: hematologic (group I, n = 57) and molecular (group 2, n = 5) relapse. In group I, 51 received RO7283420 intravenously (IV) and 6 subcutaneously. The IV doses ranged from 0.
View Article and Find Full Text PDF